Shares of Alaunos Therapeutics (NASDAQ:TCRT) collapsed more than 50% halfway through today’s trading session. The fall in price might be attributable to a unfavorable update that was released regarding a patient in the company’s TCR-T cell therapy trial.
Nevertheless, investors who got into the stock at the beginning of the year are still up almost 200% on a year-to-date basis. In addition, Alaunos is set to report early study data at a scientific conference later on in the third quarter.
